Meeting on the Mesa 2021 | Cell therapies for cone-rod dystrophy

Marie Csete, MD, PhD, ConeSight Therapeutics, Pasadena, CA, discusses the development of cone progenitor cell therapies. Whilst advanced therapies in the ophthalmological space have mainly focused on retinal pigment epithelium (RPE) cells, developing cone-based cell therapies remain behind due to difficulties in regenerating cones from stem cells. Current advancements in cone progenitor cell therapies have been designed for cone rod dystrophies, with the hope of expansion to other indications including retinitis pigmentosa (RP) and macular degeneration. This interview took place at Meeting on the Mesa 2021.